01-10-2018 | Review Article
Targeted Therapies in the Treatment of Sarcomas
Published in:
Targeted Oncology
|
Issue 5/2018
Login to get access
Abstract
About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or experimental molecularly targeted agents in the clinic. In addition, immunotherapies may have a growing role in the treatment of sarcomas in the future.